
June 24 (Reuters) - Immunic Inc IMUX.O:
IMMUNIC REPORTS NEW, POSITIVE LONG-TERM OPEN-LABEL EXTENSION DATA FROM PHASE 2 EMPHASIS TRIAL OF VIDOFLUDIMUS CALCIUM IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
IMMUNIC INC - TRIAL ACHIEVED PRIMARY AND SECONDARY ENDPOINTS WITH HIGH SIGNIFICANCE